Ribo Life Science Co., Ltd. (HKG: 6938) announced that the Automated Intelligent Drug Screening Center of its wholly‑owned subsidiary Ruibotec (Shandong) Biomedical Technology Co., Ltd. has been officially completed. Built on a cluster of automated robotics and an intelligent data‑analysis infrastructure, the facility establishes a standardised technology platform tailored for early‑stage small nucleic acid (siRNA) drug discovery and preclinical research, marking a critical leap in the company’s automation, digitalisation and intelligentisation of siRNA R&D.
Corporate Milestone
| Item | Detail |
|---|---|
| Company | Ribo Life Science Co., Ltd. (HKG: 6938) |
| Subsidiary | Ruibotec (Shandong) Biomedical Technology Co., Ltd. (wholly‑owned) |
| Facility | Automated Intelligent Drug Screening Center – officially completed |
| Core Infrastructure | Automated robot clusters + intelligent data‑analysis base |
| Purpose | Standardised platform for early siRNA drug discovery and preclinical research |
| Strategic Significance | Key milestone in automation, digitalisation and intelligent R&D |
Facility Capabilities & Technology Platform
- Throughput & Quality: The centre will significantly enhance experimental throughput, standardisation and data quality for early siRNA drug discovery and exploratory research.
- Closed‑Loop AI Integration: Deeply connected to Ribo’s existing AI‑assisted R&D system, enabling bidirectional data flow and real‑time iteration between algorithmic models and high‑throughput wet‑lab experiments.
- Proprietary Software: Built on the company’s in‑house sequence design and screening software platform for small nucleic acids.
- Capability Stack: Computer‑Aided Drug Design (CADD), AI‑Driven Drug Discovery (AIDD) and Model‑Informed Drug Development (MIDD), forming an integrated software‑hardware R&D infrastructure matrix.
- Ecosystem Partnerships: Collaborations with AI for Science partners including Insilico Medicine, Pherion, PatSnap, Benyao Technology and DP Technology, jointly targeting key links of the siRNA R&D chain.
- End‑to‑End AI Coverage: An AI‑enabled R&D system spanning target evaluation, molecular design, delivery technology and clinical development, improving decision quality and accelerating translation from source innovation to the clinic.
Pipeline Snapshot
| Stage | Assets |
|---|---|
| Clinical‑stage assets | 7 |
| Preclinical assets | 20+ |
| Early‑stage R&D projects | 45+ |
| Therapeutic Areas | Cardiovascular, metabolic, renal and liver diseases – major areas of unmet clinical need |
| Delivery Technology | Self‑developed liver‑targeting platform continues to mature; important breakthroughs achieved in extra‑hepatic delivery |
Market Impact & Outlook
- AI + Automation Synergy: The new screening centre amplifies the value of combining artificial intelligence with laboratory automation, improving the efficiency and predictability of siRNA drug development.
- Full‑Chain Acceleration: Faster cadence from target discovery and molecular design through to clinical advancement, driving accelerated conversion of siRNA innovation into clinical applications.
- Pipeline Momentum: Ribo is entering a phase of accelerated pipeline value release, with maturing liver‑targeted delivery and a breakthrough in extra‑hepatic delivery expanding its addressable disease landscape.
- Competitive Positioning: As a pioneer in the small nucleic acid field, the company’s integrated proprietary software, robotics and AI ecosystem partnerships reinforce its position in the rapidly evolving siRNA therapeutics market.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Ribo Life Science’s R&D infrastructure, pipeline advancement and commercial expectations. Actual results may differ due to risks including clinical development outcomes, technology integration timelines, and competitive dynamics in the siRNA therapeutics market.-Fineline Info & Tech
